Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
GXAI
Gaxos.ai
Sponsored
content by Gaxos.ai
JO
Jolt_Communications
Community Contributor
Gaxos.ai: Early-Stage AI Innovator in Gaming & Health
Key Takeaways Dual AI focus – Gaxos.ai builds AI-powered tools for game developers (via Unity integrations) and AI-driven health services under its RNK Health brand. First signs of commercial traction – After years of development, the company reported ~$194k in H1 2025 revenue, mainly from wellness pilot programs.
View narrative
US$2.21
FV
5.9% undervalued
intrinsic discount
119.00%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
1
users have commented on this narrative
32
users have followed this narrative
Updated
narrative
Microsoft
PI
PicaCoder
Community Contributor
After the AI Party: A Sobering Look at Microsoft's Future
The world has been captivated by the artificial intelligence boom, and no company has ridden the wave of investor enthusiasm quite like Microsoft. Buoyed by its strategic partnership with OpenAI and the integration of AI across its product ecosystem, the company's valuation has soared to unprecedented heights.
View narrative
US$500.00
FV
1.4% overvalued
intrinsic discount
6.75%
Revenue growth p.a.
Set Fair Value
21
users have liked this narrative
12
users have commented on this narrative
27
users have followed this narrative
13 days ago
author updated this narrative
Amazon.com
ZW
Zwfis
Community Contributor
Amazon's Future Rises as Stock Price Falls: A Long-Term Investment Vision
Amazon is a stock I am very interested in right now especially with the recent price drops that it has been experiencing since its 2Q25 results. A summary of Amazon as stated by Fiscal.ai: "Amazon.com, Inc.
View narrative
US$234.75
FV
2.5% undervalued
intrinsic discount
13.60%
Revenue growth p.a.
Set Fair Value
20
users have liked this narrative
7
users have commented on this narrative
25
users have followed this narrative
New
narrative
Verve Group
TI
TibiT
Community Contributor
Verve Group: A Tale of Three Futures
Verve Group stands at a critical juncture. After a history of explosive growth, the company has been hit by significant operational headwinds, primarily the difficult and costly migration to a unified technology platform and unfavorable currency exchange rates.
View narrative
€4.02
FV
44.5% undervalued
intrinsic discount
8.50%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
0
users have commented on this narrative
15
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
New Hope
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
ESG Pressures And Renewable Transitions Will Lower Coal Demand
Key Takeaways Heavy dependence on coal and tightening ESG policies threaten long-term revenue stability, asset value, and access to affordable capital. Rising costs, regulatory pressures, and clean energy advances are expected to erode profitability and shrink the company's future market.
View narrative
AU$2.80
FV
55.7% overvalued
intrinsic discount
5.78%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Viatris
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
Regulatory Burdens Will Squeeze Margins Though Pipeline Will Offer Little
Key Takeaways Sustained pricing and regulatory pressures are likely to compress margins and increase operating costs across Viatris' core generics business. Heavy debt load and reliance on mature products limit flexibility for growth investments and heighten risks to revenue stability and cash flow.
View narrative
US$8.00
FV
33.1% overvalued
intrinsic discount
0.38%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Novavax
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
Heightened Regulation And A Narrow Portfolio Will Shrink Margins
Key Takeaways Heavy reliance on a limited vaccine portfolio and partners increases vulnerability to market saturation, operational risks, and diminishing revenue after short-term gains. Intensifying regulatory scrutiny and competition from larger players threaten margins, limit growth opportunities, and hinder Novavax's long-term profitability.
View narrative
US$6.00
FV
30.7% overvalued
intrinsic discount
-53.68%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
MP Materials
AN
AnalystLowTarget
Consensus Narrative from 10 Analysts
Rapid Recycling And Oversupply Will Erode Core Margins
Key Takeaways Rising rare earth recycling and alternative battery technologies threaten structural demand for MP's core products and could weaken future revenue growth and pricing power. Heavy reliance on a single resource and execution risks in expansion projects expose MP to operational disruptions and sustained margin pressure amid global supply increases.
View narrative
US$30.00
FV
126.3% overvalued
intrinsic discount
60.14%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
TeraWulf
AN
AnalystLowTarget
Consensus Narrative from 11 Analysts
Google Backstop And Fluidstack Reliance Will Heighten Operational Risk
Key Takeaways Heavy investment in capacity and reliance on a few key clients exposes TeraWulf to pronounced operational, regulatory, and technological disruptions. Rising financing needs and tightening regulation pose risks to profitability, while rapid tech shifts could undermine its fundamental business model.
View narrative
US$7.59
FV
20.8% overvalued
intrinsic discount
68.31%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Iovance Biotherapeutics
AN
AnalystLowTarget
Consensus Narrative from 10 Analysts
Rising Interest Rates And Dilution Will Stifle TIL Progress
Key Takeaways Sustained high costs, complex distribution, and slow commercialization delay profitability and threaten market share amid rising competition from newer cancer therapies. Ongoing financial challenges, including exposure to interest rates and revenue pressure from drug pricing scrutiny, heighten risk of shareholder dilution and reduced margins.
View narrative
US$1.00
FV
169.0% overvalued
intrinsic discount
29.03%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Ryman Healthcare
AN
AnalystLowTarget
Consensus Narrative from 4 Analysts
Rising Interest Rates And Policy Risks Will Hamper Aged Care
Key Takeaways Heightened exposure to interest rate risk, housing market cycles, and regulatory changes is constraining profitability, project pipeline, and earnings predictability. Demographic and labor trends, including declining resident wealth and rising workforce challenges, threaten sustained demand and drive up long-term operating costs.
View narrative
NZ$2.51
FV
1.2% undervalued
intrinsic discount
6.40%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Redwire
AN
AnalystLowTarget
Consensus Narrative from 9 Analysts
Escalating Overruns Will Mar NASA Ties Yet Allow Cautious Recovery
Key Takeaways Persistent cost volatility, supply chain risks, and delayed commercialization create unstable revenues and ongoing pressures on margin improvement. Competitive threats and high leverage challenge Redwire's ability to achieve sustainable long-term growth and financial stability.
View narrative
US$10.00
FV
9.0% undervalued
intrinsic discount
47.34%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
KULR
KULR Technology Group
AN
AnalystLowTarget
Consensus Narrative from 2 Analysts
Heavy Dilution And Bitcoin Volatility Will Hinder Growth But Electrification Trends Will Spur Recovery
Key Takeaways Heavy reliance on external capital and strategic bets like Bitcoin create earnings volatility and risk shareholder dilution, despite potential industry tailwinds. Intense competition, rapid standardization, and operational execution challenges threaten KULR's ability to scale higher-margin products and maintain sustained, profitable growth.
View narrative
US$12.00
FV
58.5% undervalued
intrinsic discount
73.49%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Value any company in seconds
Popular companies